About Tenpoint Therapeutics
Tenpoint Therapeutics is a company based in Cambridge (United Kingdom) founded in 2020 by Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, and Deniz Dalkara. It operates as a HealthTech. Tenpoint Therapeutics has raised $155 million across 4 funding rounds from investors including Eight Roads Ventures, UCL Technology Fund and British Patient Capital. Tenpoint Therapeutics offers products and services including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment. Tenpoint Therapeutics operates in a competitive market with competitors including Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
- Headquarter Cambridge, United Kingdom
- Founders Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, Deniz Dalkara
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website tenpointtherapeutics.com
- Social LinkedIn X Instagram
- Legal Name Tenpoint Therapeutics, Ltd.
- Net Profit-$12.25 M (USD)-131as on Dec 31, 2022
- EBITDA-$13.27 M (USD)-136as on Dec 31, 2022
- Total Equity Funding$155 M (USD)
in 4 rounds
- Latest Funding Round$150 M (USD), Debt – Conventional
Jan 2026
- InvestorsEight Roads Ventures
& 10 more
Products & Services of Tenpoint Therapeutics
Tenpoint Therapeutics offers a comprehensive portfolio of products and services, including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Developed for treating presbyopia in aging eyes.
Formulated to address cataracts in aging patients.
Designed to treat geographic atrophy in eyes.
Funding Insights of Tenpoint Therapeutics
Tenpoint Therapeutics has successfully raised a total of $155M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $150 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155.0M
- Total Rounds 4
- Last Round Debt – Conventional — $150.0M
- Investors Count 11
All 4 funding rounds of Tenpoint Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $85.0M | Series B | – | Janus Henderson Investors , EQT | |
| Jan 2026 | $150.0M | Debt – Conventional | – | – | |
| Jul 2023 | $70.0M | Series A | – | British Patient Capital , F-Prime Capital | |
| Jun 2021 | – | Seed | – | EQT | – |
11 investors in total: 11 institutional.
Investors in Tenpoint Therapeutics
Tenpoint Therapeutics has secured backing from 11 investors, including venture fund investors. Prominent investors backing the company include Eight Roads Ventures, UCL Technology Fund and British Patient Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital co-investments are made in UK later-stage businesses. | – | britishpatientcapital.co.uk | Sheffield, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Healthcare companies are funded by Qiming, a venture capital firm. | – | qimingvcusa.com | Cambridge, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Venture capital firm focused on physical and life sciences companies | 2015 | ucltf.co.uk | London, United Kingdom | |
EQT is recognized as a global investment organization focused on value creation. | – | eqtgroup.com | - | |
- | – | janushenderson.com | - | |
- | – | hillhouseinvestment.com | - | |
- | – | british-business-bank.co.uk | - |
Investor details for Tenpoint Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tenpoint Therapeutics
10 people are tracked at Tenpoint Therapeutics (9 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Jose Alain Sahel | Co-Founder | Leadership |
Lyndon Da Cruz | Co-Founder | Leadership |
Thomas Reh | Co-Founder | Leadership |
Vanessa King | Co-Founder | Leadership |
Pete Coffey | Co-Founder | Leadership |
Olivier Goureau | Co-Founder | Leadership |
Deniz Dalkara | Co-Founder | Leadership |
Eddy Anglade | CEO | Leadership |
Sarah Tuller | Chief Regulatory Officer | Leadership |
Sarah Decembrini | Senior Scientist, Preclinical Ophthalmology | Team |
Complete people profiles for Tenpoint Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tenpoint Therapeutics
3 dated milestones of Tenpoint Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Tenpoint Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional, of $150.0M.
Competitors of Tenpoint Therapeutics
Tenpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| criver.com | 1947 | Wilmington, United States | – | 21,400 | Provider of drug discovery and preclinical development services | |
| annexonbio.com | 2011 | San Francisco, United States | $256.0M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| cytel.com | 1987 | Cambridge, United States | $2.0M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| aldeyra.com | 2004 | Lexington, United States | $4.8M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| labcorp.com | 1969 | Burlington, United States | – | 9,321 | Provider of laboratory tests for physicians | |
| nicox.com | 1996 | Valbonne, France | $271.0M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| precisionmedicinegrp.com | 2012 | Bethesda, United States | $257.2M | 2,151 | Provider of clinical research, development, and commercialization services for life sciences | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| frontagelab.com | 2001 | Exton, United States | $10.2M | – | Early drug development services are provided for pharma firms. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. |
Detailed competitors of Tenpoint Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tenpoint Therapeutics
The website of Tenpoint Therapeutics (tenpointtherapeutics.com) receives about 5.4K visits a month.
- Monthly visits5.4K
▲ 17.5% vs previous month
Latest news on Tenpoint Therapeutics
Complete news archive for Tenpoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Tenpoint Therapeutics
10 companies that operate in the same segment as Tenpoint Therapeutics (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tenpoint Therapeutics
Tenpoint Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Tenpoint Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Eddy Anglade is the current CEO of Tenpoint Therapeutics.
Tenpoint Therapeutics is a funded company, having raised a total of $155M across 4 funding rounds to date.
Tenpoint Therapeutics is dedicated to pioneering treatments for rejuvenating vision in aging eyes. The company targets major ophthalmic indications such as presbyopia, cataracts, and geographic atrophy. Innovative solutions are being developed to address the largest unmet needs in eye care, with a pipeline aimed at transforming treatment paradigms. Operations span across multiple global locations to support research and development in the healthcare sector.
Tenpoint Therapeutics's top competitors include LabCorp, Annexon and Charles River Laboratories.
Tenpoint Therapeutics offers Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Tenpoint Therapeutics has 11 investors. Key investors include Eight Roads Ventures, UCL Technology Fund, British Patient Capital, F-Prime Capital, and Sofinnova Partners.
Tenpoint Therapeutics operates through Tenpoint Therapeutics, Ltd..